[From single dose to lipid forms].
López
J B
JB
Servicio de Enfermedades Infecciosas, Hospital Gómez Ulla.
Gavilán
M G
MG
D000328:Adult; D000617:Aminoglycosides; D000666:Amphotericin B / Q000008:administration & dosage / Q000493:pharmacokinetics; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D000935:Antifungal Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D002648:Child; D002986:Clinical Trials as Topic; D004337:Drug Carriers; D005260:Female; D006207:Half-Life; D006801:Humans; D007231:Infant, Newborn; D008081:Liposomes; D008297:Male; D015201:Meta-Analysis as Topic; D011247:Pregnancy
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000935:Antifungal Agents; D004337:Drug Carriers; D008081:Liposomes; D000666:Amphotericin B